

**Ind-Swift Laboratories Limited***Registered Office*SCO 850, Shivalik Enclave,
NAC Manimajra, Sector 13,
Chandigarh – 160101 INDIA

✉ info@indswiftlabs.com

☎ 0172-2730503, 2730920, 5061851-53

CIN No. L24232CH1995PLC015553

Date: 12th October, 2026**Ref: ISLL:CH:2026****The President
Corporate Relationship Department
BSE Limited
Phiroze Jeejeebhoy Towers,
25th Floor, Dalal Street,
Mumbai 400 001****The Vice President,
Listing Compliance Department,
National Stock Exchange of India Limited,
Exchange Plaza, 5th Floor
Plot No. C/2, G-Block,
Bandra Kurla Complex, Bandra (E),
Mumbai 400 051****BSE Scrip Code: 532305****NSE Symbol: INDSWFTLAB****Subject: Disclosures under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011**

Dear Sir/Ma'am,

Please find enclosed herewith disclosures received under Regulation 29(2) of SEBI (Substantial acquisition of Shares and Takeover) Regulations, 2011 received by the Company on 12th October, 2026 from Essix Biosciences Limited.

You are requested to take the same on your record.

With Regards,
For **IND-SWIFT LABORATORIES LTD.****PARDEEP VERMA** Digitally signed by
PARDEEP VERMA
Date: 2026.10.12
17:25:25 +05'30'**PARDEEP VERMA
VP-CORPORATE AFFAIRS &
COMPANY SECRETARY****Manufacturing Facilities:**

Unit I: NH-21, Village Jawaharpur, Tehsil Derabassi, District SAS Nagar (Mohali), Punjab – 140507

Unit II: Phase 1, SIDCO Industrial Growth Centre, Samba, Jammu & Kashmir - 184121

☎ 0172-2730503, 2730920, 5061851-53 ✉ info@indswiftlabs.com 🌐 www.indswiftgroup.com

Follow us:     

For verifying authenticity of this letter, please reach us by sending copy of same on hr.ho@indswiftlabs.com

Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)

Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294

Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)

Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

Date: October 12, 2026

To,
The Listing Compliance Department
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai - 400051

To,
The Listing Compliance Department,
BSE Limited
P. J. Tower, Dalal Street
Mumbai – 400001

Symbol: INDSWFTLAB

Scrip Code: 532305

Subject : Disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dear Sir/Madam,

With reference to the captioned subject, I, Himanshu Jain, Director on behalf of Essix Biosciences Limited ("Acquirer"), belonging to the Promoter and Promoter Group of Ind-Swift Laboratories Limited ("Target Company"), along with Gopal Munjal, Himanshu Jain, Navrattan Munjal, Rishav Mehta, S.R. Mehta, V.R. Mehta, Annie Mehta, Bhanavi Mehta, Divya Munjal, Ishav Mehta, Meenakshi Mehta, Neeta Munjal, Nidhi Munjal, Ravi Mehta, Sahil Munjal, Sunita Jain, Saurabh Munjal, Deepti Munjal & Daksh Mehta (hereinafter collectively referred to as "PACs") hereby inform your good office that the Acquirer, has acquired 14,00,000 (Fourteen Lakh) Equity Shares pursuant to the conversion of Fully Convertible Warrants having face value of Rs. 10/- each of the Target Company on October 08, 2026 into Equity Shares.

In this regard, please find enclosed the disclosure under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, by Essix Biosciences Limited, on behalf of the whole Promoter & Promoter group of the Company.


You are requested to take the same on records.

Thanking You,

Yours Sincerely,

For Essix Biosciences Limited

Himanshu Jain
Director



CC:

The Board of Directors

Ind-Swift Laboratories Limited


SCO:850, Shivalik Enclave, NAC, Manimajra,
Chandigarh, 160101, India

Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)
 Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294
 Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)
 Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

Disclosures under Reg. 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011

Name of the Target Company (TC)	Ind- Swift Laboratories Limited		
Names of the Acquirer and Person Acting in Concert (PAC) with the Acquirer	Essix Biosciences Limited ("Acquirer") 1. Gopal Munjal; 2. Himanshu Jain; 3. Navrattan Munjal; 4. Rishav Mehta; 5. S.R. Mehta; 6. V.R. Mehta; 7. Annie Mehta; 8. Bhanavi Mehta; 9. Divya Munjal; 10. Ishav Mehta; 11. Meenakshi Mehta; 12. Neeta Munjal; 13. Nidhi Munjal; 14. Ravi Mehta; 15. Sahil Munjal; 16. Sunita Jain; 17. Saurabh Munjal; 18. Deepti Munjal; & 19. Daksh Mehta (hereinafter collectively referred to as "PACs")		
Whether the acquirers belong to Promoter/ Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	1. National Stock Exchange of India Limited ("NSE") and 2. BSE Limited ("BSE")		
Details of the acquisition as follows	Number of Shares	% w.r.t. total share/voting capital wherever applicable	% w.r.t. total diluted share/voting capital of the TC
Before the acquisition under consideration, holding of:			
a) Shares carrying voting rights			
▪ Essix Biosciences Limited	3,28,82,521	37.81	35.00
▪ PACs	44,51,757	5.12	4.74
b) Shares in the nature of encumbrance	0	0.00	0.00
c) Voting rights (VR) otherwise than by shares	0	0.00	0.00
d) Warrants /convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC acquired/sold	0	0.00	0.00
▪ Essix Biosciences Limited	70,00,000	-	7.45
Total (a+b+c+d)	4,43,34,278	42.93	47.18



Essix Biosciences Limited

Regd. Off. : SCO 850, Shivalik Enclave, NAC Manimajra, Chandigarh - 160101 (INDIA)

Phone : +91-172-2730503, 2730920, Fax : +91-172-2730504, 2736294

Place of Business: Village Bhabat, Zirakpur Ambala Highway, Zirakpur, Mohali- Punjab (India)

Ph. +91-9317812731, CIN NO. U74999CH1993PLC033428

Details of acquisition:			
a) Shares carrying voting rights acquired/sold			
▪ Essix Biosciences Limited	14,00,000	1.58	1.49
b) Shares in the nature of encumbrance	0	0.00	0.00
c) Voting rights (VR) otherwise than by shares	0	0.00	0.00
d) Warrants /convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC acquired/sold			
Total (a+b+c+d)	14,00,000	1.58	1.49
After the acquisition/sale, holding of:			
a) Shares carrying voting rights			
▪ Essix Biosciences Limited	3,42,82,521	38.80	36.48
▪ PACs	44,51,757	5.04	4.74
b) Shares in the nature of encumbrance	0	0.00	0.00
c) Voting rights (VR) otherwise than by shares	0	0.00	0.00
d) Warrants /convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC acquired/sold			
▪ Essix Biosciences Limited	56,00,000	-	5.96
Total (a+b+c+d)	4,43,34,278	43.84	47.18
Mode of acquisition /sale	Allotment of Fully Convertible Warrants through Preferential Issue by the Target Company.		
Date of receipt of intimation of allotment of shares	October 08, 2026 (" Date of Allotment ")		
Equity share capital / total voting capital of the TC before the said acquisition	Rs. 86,96,15,580/- comprising of 8,69,61,558 Equity Shares of Rs. 10/- each		
Equity share capital/ total voting capital of the TC after the said acquisition	Rs. 88,36,15,580/- comprising of 8,83,61,558 Equity Shares of Rs. 10/- each		
Total diluted share/voting capital of the TC after the said acquisition	Rs. 93,96,15,580/- comprising of 9,39,61,558 Equity Shares of Rs. 10/- each		

For Essix Biosciences Limited


Himanshu Jain
Director



Date: October 12, 2026